CA2901346C - Chimeric vaccine antigens against hepatitis c virus - Google Patents

Chimeric vaccine antigens against hepatitis c virus Download PDF

Info

Publication number
CA2901346C
CA2901346C CA2901346A CA2901346A CA2901346C CA 2901346 C CA2901346 C CA 2901346C CA 2901346 A CA2901346 A CA 2901346A CA 2901346 A CA2901346 A CA 2901346A CA 2901346 C CA2901346 C CA 2901346C
Authority
CA
Canada
Prior art keywords
hcv
amino acids
antigens
chimeric
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2901346A
Other languages
English (en)
French (fr)
Other versions
CA2901346A1 (en
Inventor
Santiago Duenas Carrera
Daylen AGUILAR NORIEGA
Yalena Amador Canizares
Liz Alvarez-Lajonchere Ponce De Leon
Gillian Martinez Donato
Sonia Gonzalez Blanco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centro de Ingenieria Genetica y Biotecnologia CIGB
Original Assignee
Centro de Ingenieria Genetica y Biotecnologia CIGB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro de Ingenieria Genetica y Biotecnologia CIGB filed Critical Centro de Ingenieria Genetica y Biotecnologia CIGB
Publication of CA2901346A1 publication Critical patent/CA2901346A1/en
Application granted granted Critical
Publication of CA2901346C publication Critical patent/CA2901346C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/29Hepatitis virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24271Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2901346A 2012-11-05 2013-10-28 Chimeric vaccine antigens against hepatitis c virus Expired - Fee Related CA2901346C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU20120153A CU24112B1 (es) 2012-11-05 2012-11-05 Antígenos vacunales quiméricos contra el virus de la hepatitis c
CU2012-0153 2012-11-05
PCT/CU2013/000006 WO2014067498A1 (es) 2012-11-05 2013-10-28 Antígenos vacunales quiméricos contra el virus de la hepatitis c

Publications (2)

Publication Number Publication Date
CA2901346A1 CA2901346A1 (en) 2014-05-08
CA2901346C true CA2901346C (en) 2019-04-23

Family

ID=49724426

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2901346A Expired - Fee Related CA2901346C (en) 2012-11-05 2013-10-28 Chimeric vaccine antigens against hepatitis c virus

Country Status (15)

Country Link
US (1) US9676825B2 (en:Method)
EP (1) EP2915544B1 (en:Method)
JP (1) JP6259831B2 (en:Method)
KR (1) KR102093495B1 (en:Method)
CN (1) CN104837498B (en:Method)
AR (1) AR093341A1 (en:Method)
AU (1) AU2013339846B2 (en:Method)
CA (1) CA2901346C (en:Method)
CU (1) CU24112B1 (en:Method)
ES (1) ES2644801T3 (en:Method)
IN (1) IN2015DN03925A (en:Method)
MX (1) MX358507B (en:Method)
RU (1) RU2639504C2 (en:Method)
WO (1) WO2014067498A1 (en:Method)
ZA (1) ZA201503036B (en:Method)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10300131B2 (en) 2015-07-07 2019-05-28 The Governors Of The University Of Alberta Hepatitis C virus immunogenic compositions and methods of use thereof
EP3515483A4 (en) * 2016-09-21 2020-12-16 The Governors of the University of Alberta HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND THEIR USE PROCEDURES
WO2018200892A1 (en) * 2017-04-27 2018-11-01 The Trustees Of The University Of Pennsylvania NUCLEOSIDE-MODIFIED mRNA-LIPID NANOPARTICLE LINEAGE VACCINE FOR HEPATITIS C VIRUS
AU2019233861A1 (en) 2018-03-16 2020-10-01 The Governors Of The University Of Alberta Hepatitis C virus peptide compositions and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ518999A (en) * 1999-11-19 2002-12-20 Csl Ltd Vaccine compositions
US6544780B1 (en) * 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
CU23496A1 (es) * 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech Composición vacunal contra el virus de la hepatitis c
CA2636032C (en) * 2006-01-04 2016-04-12 Novartis Vaccines And Diagnostics, Inc. Activation of hcv-specific t cells
US7256008B2 (en) 2006-01-06 2007-08-14 Abbott Laboratories Determination of concentration of FK778 by competitive immunoassay
WO2009056535A2 (en) * 2007-10-29 2009-05-07 Genimmune N.V. Methods and kits for inducing a ctl response using a prime boost regimen
CN102016026B (zh) * 2008-04-25 2014-07-02 东丽株式会社 含有来自丙型肝炎病毒的嵌合基因的核酸
JP2012503011A (ja) * 2008-09-19 2012-02-02 グローブイミューン,インコーポレイテッド 慢性c型肝炎ウイルス感染の免疫療法
US20110311550A1 (en) * 2008-10-24 2011-12-22 The Scripps Research Institute Agents for hcv treatment

Also Published As

Publication number Publication date
JP6259831B2 (ja) 2018-01-10
AU2013339846A1 (en) 2015-05-14
RU2015121429A (ru) 2016-12-27
CU24112B1 (es) 2015-08-27
CN104837498A (zh) 2015-08-12
CN104837498B (zh) 2018-05-18
WO2014067498A1 (es) 2014-05-08
CA2901346A1 (en) 2014-05-08
JP2015536936A (ja) 2015-12-24
KR102093495B1 (ko) 2020-03-26
KR20150079694A (ko) 2015-07-08
AU2013339846B2 (en) 2017-08-17
CU20120153A7 (es) 2014-06-27
US20150307558A1 (en) 2015-10-29
EP2915544B1 (en) 2017-08-09
US9676825B2 (en) 2017-06-13
EP2915544A1 (en) 2015-09-09
MX2015005651A (es) 2015-08-20
ZA201503036B (en) 2016-01-27
ES2644801T3 (es) 2017-11-30
RU2639504C2 (ru) 2017-12-21
AR093341A1 (es) 2015-06-03
IN2015DN03925A (en:Method) 2015-10-02
MX358507B (es) 2018-08-22

Similar Documents

Publication Publication Date Title
KR100875483B1 (ko) 백신 조성물
Zingaretti et al. Why is it so difficult to develop a hepatitis C virus preventive vaccine?
CA2901346C (en) Chimeric vaccine antigens against hepatitis c virus
Olivera et al. Protective cellular immune response against hepatitis C virus elicited by chimeric protein formulations in BALB/c mice
US8691234B2 (en) Vaccine formulation potentiated by the combination of DNA and an antigen
KR101245154B1 (ko) 간염 c 바이러스에 대한 백신 조성물
AU746258B2 (en) Genetic immunization with nonstructural proteins of hepatitis C virus
US20070032444A1 (en) Genetic immunization with nonstructural proteins of hepatitis C virus
Guillén et al. Desarrollo de plataforma de adyuvación para vacunas preventivas y terapeúticas basada en partículas semejantes a virus: demostración de efecto en modelos animales y humanos
EP1787656A1 (en) Recombinant live fowlpox virus vectors and their use in pharmaceutical compositions against hepatitis c virus
Guillén et al. Development of a technological framework for using virus-like particles as adjuvants in prophylactic and therapeutic vaccines: demonstration of effect in animal models and humans
JP2008508890A6 (ja) 組換え生鶏痘ウィルスベクター及びc型肝炎ウィルスに対する薬剤組成物中でのそれらの使用
HK1109069B (en) Vaccine composition against hepatitis c virus

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180720

MKLA Lapsed

Effective date: 20201028